Regulation of vascular endothelial growth factor by tamoxifen in vitro and in vivo

Gynecologic and Obstetric Investigation

Volumn 55, Issue 2, 2003, Pages 119-124

  Mueller, Michael D ^a   Pritts, Elizabeth A ^b   Zaloudek, Charles J ^b   Dreher, Ekkehard ^a   Taylor, Robert N ^b  

^a UNIVERSITY OF BERN   (Switzerland)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Angiogenesis; Endometrium; Tamoxifen; Vascular endothelial growth factor

Indexed keywords

ESTROGEN RECEPTOR ALPHA; ESTROGEN RECEPTOR BETA; LUCIFERASE; TAMOXIFEN; VASCULOTROPIN;

ARTICLE; CONTROLLED STUDY; DRUG EFFECT; DRUG EXPOSURE; ENDOMETRIUM BIOPSY; GENE EXPRESSION; GENETIC TRANSFECTION; HORMONE SUBSTITUTION; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; IN VIVO STUDY; PLASMID; POSTMENOPAUSE; PRIORITY JOURNAL; PROTEIN EXPRESSION; REGULATORY MECHANISM; STIMULATION;

EID: 0037531127     PISSN: 03787346     EISSN: None     Source Type: Journal    
DOI: 10.1159/000070190     Document Type: Article

References (32)

1. Timmerman D, Deprest J, Bourne T, Van den Berghe I, Collins W, Vergote I: A randomized trial on the use of ultrasonography or office hysteroscopy for endometrial assessment in postmenopausal patients with breast cancer who were treated with tamoxifen. Am J Obstet Gynecol 1998;179:62-70.
2. Early Breast Cancer Trialists' Collaborative Group: Tamoxifen for early breast cancer: An overview of the randomised trials. Lancet 1998;315:1451-1467.
3. Bite S: Breast cancer incidence in the breast cancer prevention trial. J Natl Cancer Inst 1998;90:648.
4. Powles T, Eeles R, Ashley S, Easton D, Chang J, Dowsett M, Tidy A, Viggers J, Davey J: Interim analysis of the incidence of breast cancer in the Royal Marsden Hospital tamoxifen randomised chemoprevention trial. Lancet 1998;11:98-101.
5. Kedar R, Bourne T, Powles T, Collins WP, Ashley SE, Cosgrove DO, Campbell S: Effects of tamoxifen on uterus and ovaries of post-menopausal women in a randomised breast cancer prevention trial. Lancet 1994;343:1318-1321.
6. Hyder S, Chiappetta C, Stancel G: Triphenyl-ethylene antiestrogens induce uterine vascular endothelial growth factor expression via their partial estrogen agonist activity. Cancer Lett 1997;120:165-171.
7. Hyder S, Nawaz Z, Chiappetta C, Stancel G: Identification of functional estrogen response elements in the gene coding for the potent angiogenic factor vascular endothelial growth factor. Cancer Res 2000;60:3183-3190.
8. Shifren J, Tseng J, Zaloudek C, Ryan IP, Meng YG, Ferrara N, Jaffe RB, Taylor RN: Ovarian steroid regulation of vascular endothelial growth factor in the human endometrium: Implications for angiogenesis during the menstrual cycle and in the pathogenesis of endometriosis. J Clin Endocrinol Metab 1996;81:3112-3118.
9. Mueller MD, Vigne J, Minchenko A, Lebovic D, Leitman D, Taylor R: Regulation of vascular endothelial growth factor (VEGF) gene transcription by estrogen receptors alpha and beta. Proc Natl Acad Sci USA 2000;97:10972-10977.
10. Tischer E, Mitchell R, Hartman T, Silva M, Gospodarowicz D, Fiddes JC, Abraham JA: The human gene for vascular endothelial growth factor: Multiple protein forms are encoded through alternative exon splicing. J Biol Chem 1991;266:11947-11954.
11. Minchenko A, Salceda S, Bauer T, Caro J: Hypoxia regulatory elements of the human vascular endothelial growth factor gene. Cell Mol Biol Res 1994;40:35-39.
12. Webb P, Lopez G, Uht R, Kushner P: Tamoxifen activation of the estrogen receptor/AP-1 pathway: Potential origin for the cell-specific estrogen like effects of antiestrogens. Mol Endocrinol 1995;9:443-456.
13. Mueller MD, Lebovic DI, Garrett E, Taylor RN: Neutrophils infiltrating the endometrium express vascular endothelial growth factor (VEGF): Potential role in endometrial angiogenesis. Fertil Steril 2000;74:107-112.
14. McCarty KJ, Miller L, Cox E, Konrath J, McCarty KS: Estrogen receptor analyses: Correlation of biochemical and immunohistochemical methods using monoclonal antireceptor antibodies. Arch Pathol Lab Med 1985;109:716-721.
15. Love R, Mazess R, Barden H, Epstein S, Newcomb PA, Jordan VC, Carbone PP, DeMets DL: Effects of tamoxifen on bone mineral density in postmenopausal women with breast cancer. N Engl J Med 1992;326:852-856.
16. Love R, Newcomb P, Wiebe D, Surawicz TS, Jordan VC, Carbone PP, DeMets DL: Effects of tamoxifen therapy on lipid and lipoprotein levels in postmenopausal patients with node-negative breast cancer. J Natl Cancer-Inst 1990;82:1327-1332.
17. Charnock-Jones D, Sharkey A, Rajput-Williams J, Burch D, Schofield JP, Fountain SA, Boocock CA, Smith SK: Identification and localization of alternately spliced mRNAs for vascular endothelial growth factor in human uterus and estrogen regulation in endometrial carcinoma cell lines. Biol Reprod 1993;48:1120-1128.
18. Stoner M, Wang F, Wormke M, Nguyen T, Samudio I, Vyhlidal C, Marme D, Finkenzeller G, Safe S: Inhibition of vascular endothelial growth factor expression in HEC1A endometrial cancer cells through interactions of estrogen receptor alpha and Sp3 proteins. J Biol Chem 2000;275:22769-22779.
19. Hata H, Kuramoto H: Immunocytochemical determination of estrogen and progesterone receptors in human endometrial adenocarcinoma cells (Ishikawa cells). J Steroid Biochem Mol Biol 1992;42:201-210.
20. Kumar V, Green S, Stack G, Berry M, Jin J, Chambon P: Functional domains of the human estrogen receptor. Cell 1987;51:941-951.
21. Fawell S, White R, Hoare S, Sydenham M, Page M, Parker M: Inhibition of estrogen receptor-DNA binding by the 'pure' antiestrogen ICI 164,384 appears to be mediated by impaired receptor dimerization. Proc Natl Acad Sci USA 1990;87:6883-6887.
22. Watanabe T, Inoue S, Ogawa S, Ishii Y, Hiroi H, Ikeda K, Orimo A, Muramatsu M: Agonistic effect of tamoxifen is dependent on cell type, ERE-promoter context, and estrogen receptor subtype: Functional difference between estrogen receptors alpha and beta. Biochem Biophys Res Commun 1997;236:140-145.
23. Berry M, Metzger D, Chambon P: Role of the two activating domains of the oestrogen receptor in the cell-type and promoter-context dependent agonistic activity of the anti-oestrogen 4-hydroxytamoxifen. EMBO J 1990;9:2811-2818.
24. Halbreich U, Kahn L: Selective oestrogen receptor modulators: Current and future brain and behaviour applications. Expert Opin Pharmacother 2000;1:1385-1398.
25. Cyr M, Thibault C, Morissette M, Landry M, Di Paolo T: Estrogen-like activity of tamoxifen and raloxifene on NMDA receptor binding and expression of its subunits in rat brain. Neuro-psychopharmacology 2001;25:242-257.
26. Fournier B, Gutzwiller S, Dittmar T, Matthias G, Steenbergh P, Matthias P: Estrogen receptor (ER)-alpha, but not ER-beta, mediates regulation of the insulin-like growth factor I gene by antiestrogens. J Biol Chem 2001;276:35444-35449.
27. Lee C, Cheng W, Chen C, Chu J, Hsieh C, Hsieh F: Angiogenesis of endometrial carcinomas assessed by measurement of intratumoral blood flow, microvessel density, and vascular endothelial growth factor levels. Obstet Gynecol 2000;96:615-621.
28. Hirai M, Nakagawara A, Oosaki T, Hayashi Y, Hirono M, Yoshihara T: Expression of vascular endothelial growth factors (VEGF-A/VEGF-1 and VEGF-C/VEGF-2) in postmenopausal uterine endometrial carcinoma. Gynecol Oncol 2001;80:181-188.
29. Fujimoto N, Katzenellenbogen B: Alteration in the agonist/antagonist balance of antiestrogens by activation of protein kinase A signaling pathways in breast cancer cells: Antiestrogen selectivity and promoter dependence. Mol Endocrinol 1994;8:296-304.
30. Deligdisch L: Effects of hormone therapy on the endometrium. Mod Pathol 1993;6:94-106.
31. Popovici R, Irwin J, Giaccia A, Giudice L: Hypoxia and cAMP stimulate vascular endothelial growth factor (VEGF) in human endometrial stromal cells: Potential relevance to menstruation and endometrial regeneration. J Clin Endocrinol Metab 1999;84:2245-2248.
32. Cohen I, Beyth Y, Altaras M, Shapira J, Tepper R, Cardoba M, Yigael D, Figer A, Fishman A, Berenhein J: Estrogen and progesterone receptor expression in postmenopausal tamoxifen-exposed endometrial pathologies. Gynecol Oncol 1997;67:8-15.